DNA-Encoded Library Market Size, Trends & Growth Report by 2034

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global DNA-Encoded Library Market Size Analysis

Global DNA-Encoded Library Market Introduction
By Product & Service
1. Introduction
  1. Product & Service By Value
2. Product
  1. By Value
  2. Kits & Reagents
    1. Kits & Reagents By Value
  3. Encoded Libraries
    1. Encoded Libraries By Value
  4. Others
    1. Others By Value
3. Services
  1. By Value
  2. Design & Synthesis Services
    1. Design & Synthesis Services By Value
  3. Screening Services
    1. Screening Services By Value
  4. Others
    1. Others By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Infectious Diseases
  1. By Value
4. Cardiovascular Diseases
  1. By Value
5. Neurological Diseases
  1. By Value
6. Autoimmune Diseases
  1. By Value
7. Metabolic Diseases
  1. By Value
8. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Hit Generation / Identification
  1. By Value
3. Hit to Lead
  1. By Value
4. Hit Validation / Optimization
  1. By Value
5. Others
  1. By Value
By End Use
1. Introduction
  1. End Use By Value
2. Pharmaceutical & Biotechnology Companies
  1. By Value
3. Contract Research Organizations
  1. By Value
4. Academic & Research Institutes
  1. By Value
5. Others
  1. By Value

North America Market Analysis

Introduction
By Product & Service
1. Introduction
  1. Product & Service By Value
2. Product
  1. By Value
  2. Kits & Reagents
    1. Kits & Reagents By Value
  3. Encoded Libraries
    1. Encoded Libraries By Value
  4. Others
    1. Others By Value
3. Services
  1. By Value
  2. Design & Synthesis Services
    1. Design & Synthesis Services By Value
  3. Screening Services
    1. Screening Services By Value
  4. Others
    1. Others By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Infectious Diseases
  1. By Value
4. Cardiovascular Diseases
  1. By Value
5. Neurological Diseases
  1. By Value
6. Autoimmune Diseases
  1. By Value
7. Metabolic Diseases
  1. By Value
8. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Hit Generation / Identification
  1. By Value
3. Hit to Lead
  1. By Value
4. Hit Validation / Optimization
  1. By Value
5. Others
  1. By Value
By End Use
1. Introduction
  1. End Use By Value
2. Pharmaceutical & Biotechnology Companies
  1. By Value
3. Contract Research Organizations
  1. By Value
4. Academic & Research Institutes
  1. By Value
5. Others
  1. By Value
U.S.
1. By Product & Service
  1. Introduction
    1. Product & Service By Value
  2. Product
    1. By Value
    2. Kits & Reagents
      1. Kits & Reagents By Value
    3. Encoded Libraries
      1. Encoded Libraries By Value
    4. Others
      1. Others By Value
  3. Services
    1. By Value
    2. Design & Synthesis Services
      1. Design & Synthesis Services By Value
    3. Screening Services
      1. Screening Services By Value
    4. Others
      1. Others By Value
2. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Infectious Diseases
    1. By Value
  4. Cardiovascular Diseases
    1. By Value
  5. Neurological Diseases
    1. By Value
  6. Autoimmune Diseases
    1. By Value
  7. Metabolic Diseases
    1. By Value
  8. Others
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Hit Generation / Identification
    1. By Value
  3. Hit to Lead
    1. By Value
  4. Hit Validation / Optimization
    1. By Value
  5. Others
    1. By Value
4. By End Use
  1. Introduction
    1. End Use By Value
  2. Pharmaceutical & Biotechnology Companies
    1. By Value
  3. Contract Research Organizations
    1. By Value
  4. Academic & Research Institutes
    1. By Value
  5. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Product & Service
1. Introduction
  1. Product & Service By Value
2. Product
  1. By Value
  2. Kits & Reagents
    1. Kits & Reagents By Value
  3. Encoded Libraries
    1. Encoded Libraries By Value
  4. Others
    1. Others By Value
3. Services
  1. By Value
  2. Design & Synthesis Services
    1. Design & Synthesis Services By Value
  3. Screening Services
    1. Screening Services By Value
  4. Others
    1. Others By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Infectious Diseases
  1. By Value
4. Cardiovascular Diseases
  1. By Value
5. Neurological Diseases
  1. By Value
6. Autoimmune Diseases
  1. By Value
7. Metabolic Diseases
  1. By Value
8. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Hit Generation / Identification
  1. By Value
3. Hit to Lead
  1. By Value
4. Hit Validation / Optimization
  1. By Value
5. Others
  1. By Value
By End Use
1. Introduction
  1. End Use By Value
2. Pharmaceutical & Biotechnology Companies
  1. By Value
3. Contract Research Organizations
  1. By Value
4. Academic & Research Institutes
  1. By Value
5. Others
  1. By Value
U.K.
1. By Product & Service
  1. Introduction
    1. Product & Service By Value
  2. Product
    1. By Value
    2. Kits & Reagents
      1. Kits & Reagents By Value
    3. Encoded Libraries
      1. Encoded Libraries By Value
    4. Others
      1. Others By Value
  3. Services
    1. By Value
    2. Design & Synthesis Services
      1. Design & Synthesis Services By Value
    3. Screening Services
      1. Screening Services By Value
    4. Others
      1. Others By Value
2. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Infectious Diseases
    1. By Value
  4. Cardiovascular Diseases
    1. By Value
  5. Neurological Diseases
    1. By Value
  6. Autoimmune Diseases
    1. By Value
  7. Metabolic Diseases
    1. By Value
  8. Others
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Hit Generation / Identification
    1. By Value
  3. Hit to Lead
    1. By Value
  4. Hit Validation / Optimization
    1. By Value
  5. Others
    1. By Value
4. By End Use
  1. Introduction
    1. End Use By Value
  2. Pharmaceutical & Biotechnology Companies
    1. By Value
  3. Contract Research Organizations
    1. By Value
  4. Academic & Research Institutes
    1. By Value
  5. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Product & Service
1. Introduction
  1. Product & Service By Value
2. Product
  1. By Value
  2. Kits & Reagents
    1. Kits & Reagents By Value
  3. Encoded Libraries
    1. Encoded Libraries By Value
  4. Others
    1. Others By Value
3. Services
  1. By Value
  2. Design & Synthesis Services
    1. Design & Synthesis Services By Value
  3. Screening Services
    1. Screening Services By Value
  4. Others
    1. Others By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Infectious Diseases
  1. By Value
4. Cardiovascular Diseases
  1. By Value
5. Neurological Diseases
  1. By Value
6. Autoimmune Diseases
  1. By Value
7. Metabolic Diseases
  1. By Value
8. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Hit Generation / Identification
  1. By Value
3. Hit to Lead
  1. By Value
4. Hit Validation / Optimization
  1. By Value
5. Others
  1. By Value
By End Use
1. Introduction
  1. End Use By Value
2. Pharmaceutical & Biotechnology Companies
  1. By Value
3. Contract Research Organizations
  1. By Value
4. Academic & Research Institutes
  1. By Value
5. Others
  1. By Value
China
1. By Product & Service
  1. Introduction
    1. Product & Service By Value
  2. Product
    1. By Value
    2. Kits & Reagents
      1. Kits & Reagents By Value
    3. Encoded Libraries
      1. Encoded Libraries By Value
    4. Others
      1. Others By Value
  3. Services
    1. By Value
    2. Design & Synthesis Services
      1. Design & Synthesis Services By Value
    3. Screening Services
      1. Screening Services By Value
    4. Others
      1. Others By Value
2. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Infectious Diseases
    1. By Value
  4. Cardiovascular Diseases
    1. By Value
  5. Neurological Diseases
    1. By Value
  6. Autoimmune Diseases
    1. By Value
  7. Metabolic Diseases
    1. By Value
  8. Others
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Hit Generation / Identification
    1. By Value
  3. Hit to Lead
    1. By Value
  4. Hit Validation / Optimization
    1. By Value
  5. Others
    1. By Value
4. By End Use
  1. Introduction
    1. End Use By Value
  2. Pharmaceutical & Biotechnology Companies
    1. By Value
  3. Contract Research Organizations
    1. By Value
  4. Academic & Research Institutes
    1. By Value
  5. Others
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Product & Service
1. Introduction
  1. Product & Service By Value
2. Product
  1. By Value
  2. Kits & Reagents
    1. Kits & Reagents By Value
  3. Encoded Libraries
    1. Encoded Libraries By Value
  4. Others
    1. Others By Value
3. Services
  1. By Value
  2. Design & Synthesis Services
    1. Design & Synthesis Services By Value
  3. Screening Services
    1. Screening Services By Value
  4. Others
    1. Others By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Infectious Diseases
  1. By Value
4. Cardiovascular Diseases
  1. By Value
5. Neurological Diseases
  1. By Value
6. Autoimmune Diseases
  1. By Value
7. Metabolic Diseases
  1. By Value
8. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Hit Generation / Identification
  1. By Value
3. Hit to Lead
  1. By Value
4. Hit Validation / Optimization
  1. By Value
5. Others
  1. By Value
By End Use
1. Introduction
  1. End Use By Value
2. Pharmaceutical & Biotechnology Companies
  1. By Value
3. Contract Research Organizations
  1. By Value
4. Academic & Research Institutes
  1. By Value
5. Others
  1. By Value
UAE
1. By Product & Service
  1. Introduction
    1. Product & Service By Value
  2. Product
    1. By Value
    2. Kits & Reagents
      1. Kits & Reagents By Value
    3. Encoded Libraries
      1. Encoded Libraries By Value
    4. Others
      1. Others By Value
  3. Services
    1. By Value
    2. Design & Synthesis Services
      1. Design & Synthesis Services By Value
    3. Screening Services
      1. Screening Services By Value
    4. Others
      1. Others By Value
2. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Infectious Diseases
    1. By Value
  4. Cardiovascular Diseases
    1. By Value
  5. Neurological Diseases
    1. By Value
  6. Autoimmune Diseases
    1. By Value
  7. Metabolic Diseases
    1. By Value
  8. Others
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Hit Generation / Identification
    1. By Value
  3. Hit to Lead
    1. By Value
  4. Hit Validation / Optimization
    1. By Value
  5. Others
    1. By Value
4. By End Use
  1. Introduction
    1. End Use By Value
  2. Pharmaceutical & Biotechnology Companies
    1. By Value
  3. Contract Research Organizations
    1. By Value
  4. Academic & Research Institutes
    1. By Value
  5. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Product & Service
1. Introduction
  1. Product & Service By Value
2. Product
  1. By Value
  2. Kits & Reagents
    1. Kits & Reagents By Value
  3. Encoded Libraries
    1. Encoded Libraries By Value
  4. Others
    1. Others By Value
3. Services
  1. By Value
  2. Design & Synthesis Services
    1. Design & Synthesis Services By Value
  3. Screening Services
    1. Screening Services By Value
  4. Others
    1. Others By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Infectious Diseases
  1. By Value
4. Cardiovascular Diseases
  1. By Value
5. Neurological Diseases
  1. By Value
6. Autoimmune Diseases
  1. By Value
7. Metabolic Diseases
  1. By Value
8. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Hit Generation / Identification
  1. By Value
3. Hit to Lead
  1. By Value
4. Hit Validation / Optimization
  1. By Value
5. Others
  1. By Value
By End Use
1. Introduction
  1. End Use By Value
2. Pharmaceutical & Biotechnology Companies
  1. By Value
3. Contract Research Organizations
  1. By Value
4. Academic & Research Institutes
  1. By Value
5. Others
  1. By Value
Brazil
1. By Product & Service
  1. Introduction
    1. Product & Service By Value
  2. Product
    1. By Value
    2. Kits & Reagents
      1. Kits & Reagents By Value
    3. Encoded Libraries
      1. Encoded Libraries By Value
    4. Others
      1. Others By Value
  3. Services
    1. By Value
    2. Design & Synthesis Services
      1. Design & Synthesis Services By Value
    3. Screening Services
      1. Screening Services By Value
    4. Others
      1. Others By Value
2. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Infectious Diseases
    1. By Value
  4. Cardiovascular Diseases
    1. By Value
  5. Neurological Diseases
    1. By Value
  6. Autoimmune Diseases
    1. By Value
  7. Metabolic Diseases
    1. By Value
  8. Others
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Hit Generation / Identification
    1. By Value
  3. Hit to Lead
    1. By Value
  4. Hit Validation / Optimization
    1. By Value
  5. Others
    1. By Value
4. By End Use
  1. Introduction
    1. End Use By Value
  2. Pharmaceutical & Biotechnology Companies
    1. By Value
  3. Contract Research Organizations
    1. By Value
  4. Academic & Research Institutes
    1. By Value
  5. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

DNA-Encoded Library Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Aurigene Pharmaceutical Services Ltd.
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
BioDuro
BOC Sciences
Charles River Laboratories International, Inc.
Creative Diagnostics
DyNAbind GmbH
GenScript
HitGen Ltd.
LGC Bioresearch Technologies
Life Chemicals Inc.
Merck KGaA
Pharmaron
Philochem AG
SPT Labtech Ltd
Vipergen ApS
WuXi AppTec Co., Ltd.
Others

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment